Abstract
Objective: Neoadjuvant chemotherapy (NACT) is a commonly utilized strategy for primary treatment of advanced epithelial ovarian cancer (EOC) in women with unresectable disease or poor surgical candidates. Minimally invasive surgery offers several advantages, including decreased postoperative morbidity, shorter hospitalization, and faster recovery; however, there are limited published data to demonstrate that these advantages are also balanced by non-inferior survival or improved time to adjuvant chemotherapy. Thus, we sought to assess whether there is a difference in time to disease recurrence as well as time to adjuvant chemotherapy in robotic (RA) versus open (OA) interval debulking surgeries (IDS).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
